Menu
Back to Journals » Hepatic Medicine: Evidence and Research » Volume 4
Update on entecavir in the management of severe forms of Hepatitis B
Authors Sacco R
Received 25 November 2011
Accepted for publication 11 March 2012
Published 15 May 2012 Volume 2012:4 Pages 39—47
DOI https://doi.org/10.2147/HMER.S16136
Review by Single anonymous peer review
Peer reviewer comments 4
Rodolfo Sacco
Department of Gastroenterology, Pisa University Hospital, Pisa, Italy
Abstract: Despite the effective management of most cases of hepatitis B virus (HBV) infection, there is still much room for improvement in the treatment of more severe cases of hepatitis B, such as those occurring in patients with decompensated cirrhosis, in transplanted subjects, and in patients with exacerbations of HBV infection. Among the treatments currently approved for the therapy of hepatitis B, entecavir determines a rapid suppression of viral load. This drug is also associated with a high genetic barrier and an overall favorable safety profile. This review provides an overview of recent evidence related to the use of entecavir in the management of the most severe forms of hepatitis B. The results obtained for this drug in real-life clinical practice are also reviewed.
Keywords: entecavir, HBV, hepatitis B, chronic hepatitis
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.